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During transcription and DNA replication, the DNA
template is overwound ahead of RNA and DNA
polymerases and relaxed by DNA topoisomerases.
Inhibitors of topoisomerases are potent anti-cancer
agents. Camptothecin traps topoisomerase I on
DNA and exerts preferential cytotoxicity toward can-
cer cells by way of its interference with the progres-
sion of replication forks. Starting with an unbiased
proteomic analysis, we find that the chromatin re-
modeling complex BAZ1B-SMARCA5 accumulates
near replication forks in camptothecin-exposed
cells. We report that BAZ1B associates with topo-
isomerase I and facilitates its access to replication
forks. Single-molecule analyses of replication struc-
tures show that BAZ1B contributes to replication
interference by camptothecin. A lack of BAZ1B con-
fers increased cellular tolerance of camptothecin.
These findings reveal BAZ1B as a key facilitator of
topoisomerase I function during DNA replication
that affects the response of cancer cells to topoisom-
erase I inhibitors.
INTRODUCTION
Highly conserved DNA topoisomerases resolve DNA supercoils
that build up during DNA replication and transcription (Pommier,
2006, 2013; Wang, 2002). Topoisomerase I (Top1) and topo-
isomerase II (Top2) preferentially localize to promoter regions
of actively transcribed genes, where they promote gene expres-
sion together with chromatin-remodeling complexes (Durand-
Dubief et al., 2010; Madabhushi et al., 2015; Puc et al., 2015;
Sperling et al., 2011). In addition to their primary roles in tran-
scription, Top1 and Top2 ensure the progression of replication
forks and the maintenance of genome stability (Bermejo et al.,
2007). Top1 notably prevents the formation of hybrid structures
between nascent transcripts and their DNA template, called300 Cell Reports 15, 300–309, April 12, 2016 ª2016 The Authors
This is an open access article under the CC BY-NC-ND license (http://R-loops, which obstruct the progress of replication forks (Sordet
et al., 2009; Tuduri et al., 2009).
Topoisomerases are targeted by potent anti-cancer drugs
(Pommier, 2006, 2013), and Top1 is the cellular target of the
interfacial inhibitor camptothecin (CPT), a plant alkaloid that
binds the interface of Top1-DNA cleavage complexes (Top1cc)
and blocks Top1 cleavage/ligation cycles (Pommier, 2009).
Although CPT is a powerful inhibitor of transcription, pioneering
studies have shown that CPT cytotoxicity in proliferating cells
results from interference between CPT-trapped Top1cc and
moving DNA replication forks (Holm et al., 1989; Hsiang et al.,
1989). CPT can induce replication-associated DNA double-
strand breaks (DSBs) via replication runoff at Top1cc complexes
(Strumberg et al., 2000). Whether or not replication-born DSBs
account for the selective toxicity of CPT toward replicating cells
is a matter of debate. Interfacial inhibitors of Top1 not only stabi-
lize Top1cc but also prevent DNA uncoiling (Koster et al., 2007).
So the mechanism of CPT-induced cell death during DNA repli-
cation may stem from the accumulation of DNA supercoils hin-
dering the progression of replication forks. Consistent with
this, low doses of CPT interfere with the progression of replica-
tion forks in the absence of detectable DSBs (Ray Chaudhuri
et al., 2012). The direct visualization of replication intermediates
by electron microscopy shows that CPT induces replication fork
reversal into four-way junction, which protects against replica-
tion runoff at Top1cc (Ray Chaudhuri et al., 2012). Clearly, the
mechanisms that determine the toxicity of CPT during DNA repli-
cation deserve further attention.
Here we examine how CPT interferes with the process of DNA
replication. Using nascent DNA proteomics, we find a network of
proteins that accumulates in the vicinity of the replication ma-
chinery within the first minutes of exposure to a mild dose of
CPT. Among these proteins, we identify the chromatin-remodel-
ing complex WICH, composed of BAZ1B and the ISWI ATPase
SMARCA5. BAZ1B binds the DNA polymerase processivity fac-
tor PCNA and targets SMARCA5 to DNA replication factories,
where it suppresses the formation of heterochromatin on newly
synthesized DNA (Poot et al., 2004). We report here that
BAZ1B promotes Top1 access to replication forks and, thereby,
determines the efficacy of replication hindrance by CPT.creativecommons.org/licenses/by-nc-nd/4.0/).
Figure 1. Proteins Enriched at CPT-Stalled Forks
(A) Proteins identified on nascent DNA are represented by the average ratio (three independent experiments) of normalized spectral counts (SpCs) detected in
CPT-treated (this study) versus non-treated (NT) samples (Lossaint et al., 2013) and ranked in the order of increasing ratio. Each dot corresponds to one protein.
(B) Table indicating the proteins enriched at least three times in average and detected in three independent experiments. The number of peptides detected byMS
is shown. The entire set of data is available in Table S1.
(C) STRING network view of proteins enriched at CPT-stalled forks is shown (http://string.embl.de).RESULTS
Systematic Identification of Protein Recruited at
Replication Forks in the Presence of CPT
To identify molecular determinants of replication interference by
Top1 inhibitors, we coupled the capture of isolation of proteins
on nascent DNA with mass spectrometry (iPOND-MS) shortly
after cell exposure to 100 nM CPT (Lossaint et al., 2013; Sirbu
et al., 2011). Replication interference by CPT reduces the length
of labeled replication tracks by 50% (Ray Chaudhuri et al.,
2012; Seiler et al., 2007). Thus, nascent DNA in untreated HeLa
S3 was pulse-labeled with EdU for 5 min (Lossaint et al., 2013),
while cells treated with 100 nM CPT were pulse-labeled for10 min with EdU, in order to yield equivalent amounts of EdU-
substituted DNA in untreated and CPT-treated cells. We purified
proteins bound to EdU-labeled DNA, and we calculated the
average ratio of normalized spectral counts for peptides identi-
fied by MS from three replicates of CPT-treated cells versus
three replicates of untreated cells. The entire dataset is available
in Table S1. Proteins were ranked in order of increasing ratios
(Figure 1A).
We identified 21 proteins with a LogRatio R 3 in three inde-
pendent experiments (Figure 1B; Table S1). This group included
the DNA repair and DNA replication proteins KU80, DNA-PKcs,
MCM2, Top2A, and LIG1; the two components of the chro-
matin-remodeling complex WICH (BAZ1B and SMARCA5); theCell Reports 15, 300–309, April 12, 2016 301
Figure 2. Transcription Is a Major Determinant of Replication Hindrance by CPT
(A) Western blot analysis of Chk1 phosphorylation on Ser345 in HeLa S3 cells exposed to CPT (1 mM) for the indicated time. When indicated, cells were pre-
treated for 3 hr with 50 mM cordycepin, 4 hr with 50 mg/ml a-amanitin, or 2 hr with 100 mM DRB.
(B) HeLa S3 and HDF cells were pre-treated with transcription inhibitors as described above, and they were labeled with IdU (30 min) and then with CldU (30 min)
in the presence of 1 mMCPT when indicated. Graphic representation shows the ratios of CldU versus IdU track length. The horizontal bar represents the median,
indicated in red, from at least 50 replication tracks per experimental condition. Differences between experiments were assayed using Mann-Whitney rank test;
p values are indicated.
(C) Frequency of reversed forks detected by electron microscopy (EM) in U2OS cells. Electron micrographs of a normal replication fork in non-treated cells and a
regressed fork from CPT-treated cells are shown. Cells were treated for 1 hr with 25 nM CPT and pretreated or not for 3 hr with 50 mM cordycepin. The total
number of analyzed molecules is given in brackets. Above each column, the percentage of reversed forks is indicated. Parental duplex, P; daughter duplex, D;
regressed arm, R; NT, non-treated.structural component of the nuclear matrix NUMA1; as well as
proteins implicated in RNA metabolism (SNRNP200, KHSRP,
PRPF8, USP39, DDX21, DHX15, SRSF3, and PCBP1). To obtain
a broader perspective on the chromatin composition in the vicin-
ity of replication forks upon inhibition of Top1, we also consid-
ered proteins that exhibited a LogRatio R 4 in two of three
independent experiments. This yielded a list of 50 proteins that
form an interconnected functional network, as revealed by
Search Tool for the Retrieval of Interacting Genes/Proteins
(STRING) database analysis (Figure 1C).
Intriguingly, near half of the proteins enriched specifically at
CPT-stalled forks were annotated as RNA-processing factors.
Since transcription activity is a major source of DNA replication
stress, we reasoned that the enrichment of RNA-processing
factors near CPT-stalled forks could reflect proximity between
transcription and DNA replication machineries. To verify the
contribution of transcription activity on DNA replication interfer-
ence by CPT (Liu and Wang, 1987), we transiently shut down302 Cell Reports 15, 300–309, April 12, 2016transcription with cordycepin, a-amanitin, or 5,6-dichloro-1-
b-D-ribofurosylbenzimidazole (DRB). Transient inhibition of tran-
scription did not alter the distribution of cells throughout the cell
cycle (Figure S1A). We used Chk1 phosphorylation on Ser345
as a marker of CPT-induced DNA replication stress signaling.
Phospho Chk1 (Ser345) signals were detected in HeLa S3
cells after 15-min exposure to CPT and accumulated thereafter
(Figure 2A). By contrast, CPT-induced Chk1 phosphorylation
was markedly reduced when the cells were pre-incubated
with the transcription inhibitors cordycepin, a-amanitin, or DRB
(Figure 2A).
Next we usedDNA fiber labeling tomeasure the progression of
replication forks in HeLa S3 cells and in primary human dermal
fibroblasts (HDFs). Replication tracks were dually labeled with
the thymidine analogs IdU and CldU for 30 min each (Merrick
et al., 2004; Seiler et al., 2007).We did not observe significant dif-
ferences in the length of IdU-labeled replication tracks synthe-
sized in the absence or presence of cordycepin, a-amanitin, or
DRB (Figure S1B), indicating that transient inhibition of transcrip-
tion activity per se did not perturb the progression of replication
forks. Then we probed the impact of transcription activity on
DNA replication interference by CPT. Under basal conditions,
the ratios of CldU versus IdU track length was close to 1 (Fig-
ure 2B; Figure S1C), as expected if replisomes progress at
constant speed. The addition of 1 mM CPT during CldU pulse-
labeling interfered with fork progression and reduced the length
of CldU tracks. Hence, the ratio of CldU/IdU tracks was dimin-
ished. By contrast, replication interference by CPT was partially
suppressed when transcription was inhibited by cordycepin,
a-amanitin, or DRB (Figure 2B; Figure S1C). Next, we visualized
replication intermediates using electron microscopy (Neelsen
et al., 2014). Upon DNA replication stress, the nascent DNA
strands can anneal and form a fourth arm extruded at the branch
point, a process known as fork reversal (Ray Chaudhuri et al.,
2012; Zellweger et al., 2015). Consistent with the notion that tran-
scription stress contributes to DNA replication interference by
CPT, the shutdown of transcription by cordycepin reduced the
proportion of regressed forks in cells exposed to CPT (Figure 2C;
Figure S1D). Altogether, these data indicate that CPT treatment
exacerbates interference between transcription and DNA repli-
cation, thereby inducing accumulation of RNA-processing fac-
tors on nascent DNA near forks.
BAZ1B and SMARCA5 Accumulate at Replication Forks
upon Top1 Inhibition
We sought to characterize specific factors actively recruited
at replication forks that determine replication hindrance by
CPT. MS analyses revealed a significant accumulation of
BAZ1B and SMARCA5 proteins at CPT-stalled forks (Figure 1B).
BAZ1B binds directly to the DNA polymerase processivity factor
PCNA and targets the ISWI ATPase SMARCA5 to replication foci
(Poot et al., 2004). The replication-dependent recruitment of this
chromatin-remodeling complex on nascent DNA prompted us to
examine the impact of BAZ1B function at replication forks during
CPT treatment.
To validate iPOND-MS data, we repeated the iPOND and
verified the binding of SMARCA5 and BAZ1B to nascent DNA
by western blotting. Under basal conditions, weak signals
corresponding to BAZ1B and SMARCA5 were detectable in
pull-downs of EdU-labeled DNA, as reported previously (Lo-
pez-Contreras et al., 2013; Sirbu et al., 2013). In the presence
of CPT, however, the amount of SMARCA5 and BAZ1B bound
to nascent DNA increased (Figure 3A). BAZ1B, SMARCA5, and
PCNA signals were lost upon chase with thymidine, indicating
that these proteins travel with replisomes (Figure 3A). When cells
were treated with CPT for 10 min after thymidine chase, neither
SMARCA5 nor BAZ1B was detected in EdU pull-downs that
lacked PCNA (Figure 3B). This result confirms that CPT induces
the accumulation of BAZ1B-SMARCA5 on nascent DNA specif-
ically near replication forks (Figure 3B).
We generated a HeLa S3 cell line that stably expressed an
anti-BAZ1B small hairpin RNA (shRNA). BAZ1B was efficiently
depleted while the level of SMARCA5 remained unaffected (Fig-
ure 3C). In the absence of BAZ1B, we did not detect SMARCA5
on nascent DNA from CPT-treated cells (Figure 3D). Altogether,
these data indicate that BAZ1B targets SMARCA5 on nascentDNA and that both proteins accumulate near replication forks
upon exposure to CPT.
BAZ1B-Depleted Cells Exhibit Increased Tolerance to
CPT
Cells lacking BAZ1B (stable shRNA or knockout using CRISPR/
Cas9) were viable, and their distribution into the cell cycle was
not altered (Figure S2A), confirming that BAZ1B is not an essen-
tial factor (Culver-Cochran and Chadwick, 2013). BAZ1B loss of
function, however, alters the profile of gene expression (Culver-
Cochran and Chadwick, 2013; Lalli et al., 2016), consistent with
the role of BAZ1B in chromatin remodeling. To confirm that the
depletion of BAZ1B does not shut down transcription, we
measured the rate of transcription activity using microscope
quantification of nascent RNA transcripts labeled with the uridine
analog EU (Adam et al., 2013). Figure 4A shows that, overall, the
levels of transcription activity in BAZ1B-depleted and control
cells are similar.
We analyzed the viability of BAZ1B-depleted cells following
exposure to increasing concentrations of CPT for 3 days.
BAZ1B-depleted cells were more tolerant to mild doses of CPT
(125–500 nM) than control cells (Figure 4B). To confirm this result,
we treated three independent BAZ1B knockout (KO) clones ob-
tained by CRISPR/Cas9 with CPT. All three clones were more
tolerant to CPT than controls cells, including two (clones 1 and 3)
that weremore tolerant to CPT thanBAZ1B knockdown cells (Fig-
ure4B). Importantly, theabsenceofBAZ1Bdidnotalter thecellular
level of Top1 (Figure S2B). Thus, increased tolerance to CPT was
not caused by the downregulation of Top1. To confirm that
BAZ1B suppression promotes cellular tolerance to CPT, we veri-
fied that CPT was still active in BAZ1B-depleted cells. Top1 is en-
riched in promoter regions of active genes (Durand-Dubief et al.,
2010; Puc et al., 2015; Sperling et al., 2011), hence CPT primarily
inhibits transcription.The incorporationofEUassociatedwith tran-
scription activity was decreased by 3-fold in both control and
BAZ1B-depleted cells (Figure 4A), indicating that the absence of
BAZ1B did not perturb the capacity of CPT to block transcription.
Next we examined if BAZ1B depletion increases tolerance to
CPT via perturbation of DNA damage checkpoints. BAZ1B is
endowed with a tyrosine kinase activity that contributes to the
regulation of the late-stage DNA damage response via H2A.X
phosphorylation on Tyr142 (Xiao et al., 2009). Consistent with
this, we observed that the depletion of BAZ1B reduced the
level of g-H2AX by 40% in HDFs exposed for 6 hr to 1 mM
CPT (Figure S2C). The depletion of BAZ1B did not induce con-
stitutive phosphorylation of Chk1 on Ser345 and of RPA32
on Ser4/8 (Figure 4C), whereas both proteins were promptly
phosphorylated upon cell exposure to CPT. The knockdown of
BAZ1B with small interfering RNAs (siRNAs) slightly altered
phospho-Chk1 (Ser345) and phospho-RPA32 (Ser4/8) signals
in HDFs, but no clear difference in checkpoint signaling was
observed in BAZ1B-depleted HeLa S3 cells (Figure 4C). This
result confirms that BAZ1B depletion did not inhibit transcrip-
tion-dependent phosphorylation of Chk1 in response to CPT
treatment, as shown in Figure 2A. In summary, the depletion of
BAZ1B promotes cellular tolerance to CPT without blocking
transcriptional activity or inducing significant alterations in
Chk1 phosphorylation.Cell Reports 15, 300–309, April 12, 2016 303
Figure 3. BAZ1B and SMARCA5 Accumulate on Nascent DNA upon CPT Treatment
(A) Western blot analysis of indicated proteins isolated by iPOND. HeLa S3 cells were pulse-labeled with EdU for 5 or 10min in the presence of 1 mMCPT, and then
chased with thymidine for 30 or 120 min, as indicated. In no-click samples (no Clk), desthiobiotin-TEG azide was replaced by DMSO.
(B) Western blot analysis of indicated proteins isolated by iPOND. HeLa S3 cells were pulse-labeled with EdU for 5 min under basal conditions or for 10 min in the
presence of 1 mMCPT, and then chased for 30min with thymidine. When indicated, cells were exposed for 10min to 1 mMCPT after 30-min chase with thymidine.
(C) Western blot analysis of the indicated proteins in HeLa S3 cells transfected with either pEB-H1-puro (Ctrl) or pEB-H1-puro shRNA BAZ1B is shown.
(D) Control and BAZ1B-depleted HeLa S3 cells were pulse-labeled for 10min with EdU in the presence of 1 mMCPT, and then chased for 120min with thymidine.
The indicated proteins were isolated by iPOND and probed by western blotting.BAZ1B Promotes Top1 Loading in the Vicinity of
Replication Forks
Using iPOND, we detected Top1 on nascent DNA near replica-
tion forks (Figure 4D). This confirmed that, like in budding yeast
(Bermejo et al., 2007), human Top1 associates with ongoing
replication forks. The dynamic recruitment of Top1 on nascent
DNA mirrored that of BAZ1B, and Top1 accumulated near repli-
cation forks upon exposure to CPT (Figure 4D), consistent with
the iPOND-MS data (Table S1). Strikingly, the depletion of
BAZ1B abolished the recruitment of Top1 to replication forks
(Figure 4D). These data indicate that BAZ1B facilitates Top1
loading during DNA replication, but is dispensable for the func-
tion of Top1 in transcription.
We probed whether BAZ1B physically associates with Top1 by
co-immunoprecipitation. Top1was not detectable in immunepre-
cipitates of endogenous BAZ1B or in pull-downs of recombinant
FLAG-BAZ1B expressed in HeLa S3 cells (data not shown). By
contrast, we efficiently captured endogenous Top1 by immuno-
affinity, as revealed by Ponceau S staining of the nitrocellulose
membrane after protein transfer (Figures 4E and 4F). Endogenous304 Cell Reports 15, 300–309, April 12, 2016BAZ1B co-immunoprecipitated with Top1, specifically. As ex-
pected, we did not detect BAZ1B in BAZ1B KO cells, confirming
signal specificity (Figure 4E). The association of BAZ1B with Top1
was induced upon cell treatment with 1 mM CPT for 30 min (Fig-
ure 4F). This association was unlikely to be mediated by bridging
DNA molecules, as BAZ1B co-immunoprecipitated with Top1 in
the presence of ethidium bromide (Figure 4F). Collectively, these
data provide evidence that BAZ1B facilitates the recruitment of
Top1 in the vicinity of replication forks.
BAZ1B Determines the Extent of CPT-Mediated
Replication Fork Slowing and Reversal
Since BAZ1B promotes Top1 loading near forks, we examined if
BAZ1B determines the capacity of CPT to hinder the progression
of replication forks. We used DNA fiber labeling to monitor fork
progression in HeLa S3 cells and in HDFs. Replication tracks
were labeled using two consecutive 30-min pulses with ldU
and CldU. The depletion of BAZ1B did not alter the average
length of ldU tracks (Figure S3A), suggesting that, under these
experimental conditions, BAZ1B does not influence the rate of
Figure 4. BAZ1B Promotes Top1 Loading in
the Vicinity of Replication Forks
(A) Global transcriptional activity visualized by
5-ethynyl uridine (EU) incorporation. Cells were
labeled with EU for 30 min with or without 1 mM
CPT. Average EU incorporation from three inde-
pendent replicates wasmeasured by fluorescence
microscopy. At least 79 cells were analyzed per
experiment. SD is indicated.
(B) Cells were treated with the indicated doses
of CPT for 3 days. The percentage of viability
was estimated using Promega CellTiter-Glo assay.
The SEM from four independent experiments is
indicated.
(C) HDFs transfected with control or anti-BAZ1B
siRNA smartpool and HeLa S3 cells expressing an
anti-BAZ1B shRNA were lysed after increasing
exposure time in 1 mM CPT, and then probed for
the indicated proteins by western blotting. Total
RPA32 signals fade away when RPA32 is phos-
phorylated, most likely owing to the dilution of the
RPA32 signal intomultiple bands corresponding to
different degree of RPA32 phosphorylation.
(D) Western blot analysis of indicated proteins
isolated on nascent DNA. Control and BAZ1B-
depleted HeLa S3 cells were pulse-labeled with
EdU for 5 or 10 min in the presence of 1 mM CPT.
(E) Western blot analysis of BAZ1B in Top1 im-
munoprecipitates from control and BAZ1B KO
HeLa S3 cells, as indicated. The bottom panel
shows the Ponceau staining of the nitrocellulose
membrane after protein transfer. Top1 yields
saturated ECL signals by western blotting.
(F) Western blot analysis of BAZ1B in Top1 im-
munoprecipitates from HeLa S3 cells treated with
1 mM CPT for 30 min, and from extracts pre-
treated with 50 mg/ml Ethidium Bromide (EtBr), as
indicated. The Ponceau-stained nitrocellulose
membrane is shown.DNA chain elongation. In striking contrast, the knockdown of
BAZ1B in HeLa S3 cells or in HDFs rescued fork progression in
the presence of CPT, as revealed by the ratio of CIdU/ldU tracks
fromcells exposed toCPT during CldU pulse-labeling (Figure 5A;CeFigure S3B). Consistent with this, CPT
did not hinder the progression of replica-
tion forks in three independent BAZ1B
KO clones obtained by CRISPR/Cas9
(Figure 5B; Figure S4A). CPT-mediated
replication interference was restored in
BAZ1B KO cells complemented with
BAZ1B cDNA (Figure 5C). Inhibition of
DNA polymerase a by aphidicolin, how-
ever, interfered with DNA synthesis as
efficiently in BAZ1B-depleted cells as in
control cells, indicating that BAZ1B does
not influence replication inhibition by a
distinct mechanism (Figure 5D; Fig-
ure S5). Last, we used electron micro-
scopy to score regressed forks in cells
treated with CPT. In comparison withcontrol cells, the percentage of regressed forks was reduced
by 30%, in BAZ1B knockdown and in BAZ1B KO cells (Fig-
ure 5E; Figure S4B), suggesting that BAZ1B activity at replication
forks contributes to topological challenges induced by CPT. Byll Reports 15, 300–309, April 12, 2016 305
Figure 5. BAZ1B Determines Replication Interference and Fork Reversal by CPT
(A) HeLa S3 cells or HDFs were labeled with IdU (30min) and then with CldU (30min) in the presence of 1 mMCPT, when indicated. Graphic representation shows
the ratios of CldU versus IdU track length. The horizontal bar represents the median, indicated in red, from at least 50 replication tracks per experimental
condition. Differences between experiments were assayed using Mann-Whitney rank test; p values are indicated.
(B) Replication tracks from HeLa S3 cells and three BAZ1B KO clones were prepared and analyzed as described in (A).
(C) Replication tracks from wild-type, BAZ1B KO, and BAZ1B KO HeLa S3 cells complemented with a cDNA encoding wild-type BAZ1B were prepared and
analyzed as described in (A).
(legend continued on next page)
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contrast, the frequency of regressed forks was similar in control
and in BAZ1B knockdown cells exposed to aphidicolin (Fig-
ure 5E; Figure S4B). Collectively, these data indicate that
BAZ1B specifically facilitates the function of Top1 and the action
of CPT at replication forks.
DISCUSSION
Inhibitors of Top1 constitute an important class of chemothera-
peutic drugs that exert cytotoxicity toward proliferating cancer
cells via interference with ongoing replication forks (Holm et al.,
1989; Hsiang et al., 1989). Our systematic analysis of proteins
enriched near CPT-stalled forks revealed a network of transcrip-
tion and pre-mRNA processing factors, suggesting that the to-
pological constraints caused by CPT increase physical proximity
between DNA replication and transcription machineries. Using
transcription inhibitors, we show here that transcription activity
contributes to replication interference by CPT, perhaps via the
induction of hybrid structures between DNA and nascent tran-
scripts, called R-loops, which represent major obstacles to the
progression of replication forks (Sollier et al., 2014; Sordet
et al., 2009; Zeman and Cimprich, 2014). Reactive aldehydes
also interfere with DNA replication in a transcription-dependent
manner via the induction of R-loops (Schwab et al., 2015). Free
radicals, UV radiation, and alkylating drugs also can block the
re-ligation of Top1cc and induce transcription stress (Meng
et al., 2003; Pourquier and Pommier, 2001; Sordet et al., 2004).
These agents generate chemical alterations in DNA that perturb
the perfect alignment of the 50 hydroxyl end and the tyrosyl-
phosphodiester bonds necessary to re-ligate Top1cc com-
plexes. Thus, as shown here for CPT, replication interference
by DNA-damaging agents that perturb Top1 cleavage/ligation
cycles could be associated with the induction of conflicts be-
tween transcription and DNA replication.
In this study, we report the identification of the replication-
associated chromatin-remodeling complex WICH (BAZ1B-
SMARCA5) as a key determinant of replication hindrance by
Top1 poisons. We do not believe that the contribution of
BAZ1B in replication hindrance by CPT is linked with an essential
function of BAZ1B in transcription. The depletion of BAZ1B did
not shut down transcription, did not perturb the capacity of
CPT to block transcription, and did not inhibit transcription-
dependent Chk1 phosphorylation upon treatment with CPT.
Cells lacking BAZ1B grow like normal cells and the KO of
BAZ1B is compatible with human life. BAZ1B is deleted along
with26–28 genes on chromosome 7q11.23 in a neurodevelop-
mental disorder known as Williams-Beuren syndrome (Francke,
1999), a condition characterized by developmental delay, cardio-
vascular anomalies, and abnormal social-emotional processing.
We present evidence that BAZ1B promotes Top1 function
during DNA replication. First, BAZ1B was necessary for Top1(D) HeLa S3 cells or HDFswere labeled with IdU (30min) and then with CldU (30mi
length were analyzed as described in (A).
(E) Frequency of reversed forks detected by EM in BAZ1B knockdown U2OS cells
verified by western blotting. GAPDH was used as a loading control. Cells were o
molecules analyzed is given in brackets. The percentage of reversed forks is ind
(F) Model: BAZ1B facilitates Top1 loading near replication forks and determinesbinding at replication forks, and both proteins accumulated on
nascent DNA upon Top1 inhibition; second, endogenous Top1
and BAZ1B co-immunoprecipitated in a CPT-inducible manner;
last, BAZ1B determined replication interference and fork
reversal by CPT. As Top1 inhibitors prevent DNA uncoiling by
Top1 (Koster et al., 2007), the accumulation of positive supercoil-
ing ahead of replication forks can be absorbed by fork reversal
(Postow et al., 2001). Consistent with BAZ1B promoting Top1
function near replication forks, the depletion of BAZ1B partially
suppressed the reversal of replication forks.
BAZ1B is recruited to replication factories through direct inter-
action with PCNA (Poot et al., 2004, 2005). We propose that
BAZ1B recruitment at forks promotes Top1 action and thereby
counteracts the accumulation of positive supercoiling ahead of
the advancing replication machine (Figure 5F). The depletion of
BAZ1B did not induce replication defects or replication stress
signaling under basal conditions, suggesting that the loading of
Top1 by BAZ1B at replication forks is not essential for DNA repli-
cation. The accumulation of supercoiled DNA during replication
may be resolved via other mechanisms. For example, if replica-
tion forks are free to swivel around their axis, torsional stress
ahead of replication forks can redistribute to the replicated sister
duplexes as pre-catenanes resolved by type II topoisomerases.
The chromatin-remodeling complex BAZ1B-SMARCA5 may
respond to the accumulation of DNA supercoiling at replication
forks via the detection of alterations in nucleosome positioning
caused by topological stress. Naked supercoiled DNA is effi-
ciently processed by topoisomerases, but nucleosomes repre-
sent an obstacle to the resolution of supercoils (Halmer and
Gruss, 1997). As CPT perturbs nucleosome turnover (Teves
and Henikoff, 2014), BAZ1B-SMARCA5 (WICH complex) may
facilitate Top1 accessibility to the vicinity of replication forks
via nucleosome remodeling. A non-mutually exclusive possibility
is that the remodeling of nucleosomes by BAZ1B-SMARCA5
near forks induces the accumulation of DNA supercoiling
resolved by Top1 (Gavin et al., 2001). The functional association
between chromatin remodeling and DNA uncoiling is not without
precedent. For example, BRG1/SMARCA4 and BAF250a/
ARID1A from the SWI/SNF BAF complex recruit topoisomerase
IIA to chromatin (Dykhuizen et al., 2013). Likewise, Top2 recruit-
ment in budding yeast depends on Snf5, a component of the
SWI/SNF complex (Sperling et al., 2011). Very recently, BRG1/
SMARCA4 and the FACT complex have been shown to be
required for Top1 recruitment at immunoglobulin loci (Husain
et al., 2016).
The non-essential function of BAZ1B in Top1 loading near
replications forks suggests in principle BAZ1B as a candidate
biomarker to guide the rational use of Top1 inhibitors. As the
anti-cancer property of Top1 inhibitors is linked with DNA repli-
cation hindrance, measurements of BAZ1B levels in tumor tis-
sues could help predict therapeutic outcomes.n) in the presence of aphidicolin (0.1 mM), as indicated. Ratios of CldU/IdU track
and in BAZ1B KO HeLa S3 cells, as indicated. The knockdown of BAZ1B was
ptionally treated for 1 hr with 25 nM CPT or 0.1 mM aphidicolin. The number of
icated. Similar results were obtained in at least one independent experiment.
the efficacy of replication interference by CPT.
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EXPERIMENTAL PROCEDURES
Cell Lines
HDFs from neonatal human foreskin were maintained in DMEM plus 10% fetal
calf serum (FCS) and L-glutamine (2 mM). HeLa S3 and human osteosarcoma
U2OS were maintained in DMEM plus 10% FCS and penicillin- streptomycin
(1%).
shRNA and siRNA
The shRNA against BAZ1B (50-GGAGATAGTTCGATACTTTAT-30) was cloned
in pEB-H1-puro (a gift from Joachim Lingner) and used to generate the stable
HeLa S3 cell line using lipofectamine (Life Technologies) for transfection.
SmartPool BAZ1B siRNA (M-006901-02-005) and control siRNA (M-001810-
02-005) were from Dharmacon. Analyses were performed 48 hr after
transfection.
CRISPR/Cas9
The two RNA guides (sequences available on request) for targeting BAZ1B
exon 2 were designed using the CRISPR design website (http://crispr.mit.
edu/) and cloned in MLM3636. The two plasmids were then co-transfected
with pHL-EF1a-SphcCas9(D10A)-iP-A that encodes the Cas9 nickase. Individ-
ual clones were tested for BAZ1B expression by western blotting. Comple-
mentation was performed using pEBAZ1B (a gift from P. Varga-Weisz), which
encodes BAZ1B under the control of CMV promoter.
MS and Label-free Quantification
Matrix-assisted laser desorption/ionization tandemMS (MS/MS) analyses and
label-free quantification were performed as described previously (Lossaint
et al., 2013).
iPOND
iPONDwas performed as described in Lossaint et al. (2013) and in the Supple-
mental Experimental Procedures.
Western Blotting
Samples were resolved by SDS-PAGE and transferred on nitrocellulose mem-
branes. Antibodies against the following proteins were used: BAZ1B (Bethyl
Laboratories, A300-446A), SMARCA5 (Bethyl Laboratories, A301-017A),
Ser345 Phospho-Chk1 (Cell Signaling Technology, 2348), Chk1 (Santa Cruz
Biotechnology, sc-8408), PCNA (Sigma-Aldrich, P8825), H3 (Santa Cruz
Biotechnology, sc-10809) Tubulin (GeneTex, GTX27749), Ser4/8 Phospho
RPA32 (Bethyl Laboratories, A300-245A), RPA32 (Calbiochem, NA18), and
Top1 (BD Pharmingen, 556597).
DNA Fiber Labeling
DNA fiber labeling was performed as described in Lossaint et al. (2013) and
in the Supplemental Experimental Procedures. Differences between experi-
ments were assayed using the Mann-Whitney rank test.
EU Incorporation
HeLa S3 cells were incubated for 30 min with 5-ethynyl uridine (EU) and fixed
with 4% paraformaldehyde. EU was coupled with Alexa fluor 555 with a Click-
iT kit (Life Technologies). Cells were analyzed by fluorescencemicroscopy and
average EU intensity was calculated using ImageJ software.
Survival and Viability
HeLa S3 cells were incubated with increasing concentrations of CPT for 3 days
and viability was estimated using CellTiter-GLO (Promega).
Electron Microscopy Analysis of DNA Replication Intermediates in
Human Cells
The procedure was essentially performed as described in Neelsen et al. (2014)
and in the Supplemental Experimental Procedures.
Co-immunoprecipitation
HeLa cells were incubated for 30 min on ice in high-salt buffer (50 mM Tris
[pH 7.5], 300 mMNaCl, 1% Triton, and 1 mMDTT). After 10-min centrifugation308 Cell Reports 15, 300–309, April 12, 2016at 14,000 3 g, supernatant was incubated with anti-Top1 antibody (Abcam,
ab109374) or IgG rabbit (Calbiochem, NI01) overnight at 4C. Magnetic beads
coupled with protein G (Life Technologies, 10004D) were added for 1 hr and
washed five times with washing buffer (10 mM HEPES, 100 mM KOAc, and
0.1 mM MgOAc). Beads were boiled in Laemmli buffer and supernatants
were analyzed by western blotting.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and one table and can be found with this article online at http://
dx.doi.org/10.1016/j.celrep.2016.03.027.
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